Expertise in
14
conditions

Xuemei W. Tang

12 Middle Urumqi Road, 
Shanghai, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
14
conditions
12 Middle Urumqi Road, 
Shanghai, CN 

Overview

Xuemei Tang practices practicing medicine in Shanghai, China.

Tang is highly rated in 14 conditions, according to our data. Their clinical expertise encompasses Juvenile Idiopathic Arthritis (JIA), Cyclic Neutropenia, Primary Immunodeficiency (PID), Bone Marrow Transplant, and Splenectomy.

They are actively involved in clinical research, co-authoring 248 peer reviewed articles and participating in 2 clinical trials.

Locations

12 Middle Urumqi Road, Shanghai, 200040, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

248 Total Publications

Plasma cfDNA and peripheral blood gDNA provide complementary information for molecular monitoring in myeloproliferative neoplasms.
Plasma cfDNA and peripheral blood gDNA provide complementary information for molecular monitoring in myeloproliferative neoplasms.
Journal: Frontiers in oncology
Published: December 19, 2025

Frequently Asked Questions about Xuemei W. Tang

Is Xuemei W. Tang a top-rated expert for Juvenile Idiopathic Arthritis (JIA)?

MediFind is an objective health platform that identifies experts based on real-world data. Xuemei W. Tang is classified as an Distinguished expert for Juvenile Idiopathic Arthritis (JIA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Xuemei W. Tang participate in research or clinical trials?

Yes. Xuemei W. Tang has published 248 articles and abstracts on conditions like Juvenile Idiopathic Arthritis (JIA). You can view a list of Xuemei W. Tang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tang's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 75 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile